Ito K, Ohtake N, Hatori M, Mashimo T, Jimbo S, Tomaru Y, Makino T, Yajima H, Imai K, Yamanaka H
Gunma Urological Oncology Study Group.
Hinyokika Kiyo. 1992 Nov;38(11):1225-9.
The usefulness of prostatic specific antigen (PA) was compared with that of prostatic acid phosphatase (PAP). PA was determined in the serum of 2,183 patient examined by the mass screening for prostate cancer from 1987 to 1990. The serum samples of these patients were obtained from our serum bank. PA was measured by the E test "TOSOH" II (PA). The relationship of PA and PAP to prostate size estimated by digital rectal examination (DRE) and ultrasound tomography (US), and age was investigated. PA and PAP correlated with aging and prostate size estimated by DRE. However PA was more apparently related with these things. The correlation between PA and prostatic size estimated by US was relatively high (r = 0.53), but the correlation between PAP and prostate size estimated by US was low (r = 0.20). When the upper limit of normal range was set at 6.0 ng/ml, the sensitivity, specificity and efficiency was 64%, 97% and 62%, respectively. PA was more sensitive than PAP and could be more useful since none of the patients with prostate cancer was PAP positive and PA negative. We conclude that PA should be a reliable tumor marker in our mass screening system.
对前列腺特异性抗原（PA）和前列腺酸性磷酸酶（PAP）的效用进行了比较。在1987年至1990年接受前列腺癌大规模筛查的2183例患者的血清中测定了PA。这些患者的血清样本取自我们的血清库。PA通过E测试“TOSOH”II（PA）进行测量。研究了PA和PAP与通过直肠指检（DRE）和超声断层扫描（US）估计的前列腺大小以及年龄之间的关系。PA和PAP与通过DRE估计的衰老和前列腺大小相关。然而，PA与这些因素的相关性更明显。PA与通过US估计的前列腺大小之间的相关性相对较高（r = 0.53），但PAP与通过US估计的前列腺大小之间的相关性较低（r = 0.20）。当正常范围的上限设定为6.0 ng/ml时，敏感性、特异性和效率分别为64%、97%和62%。PA比PAP更敏感，可能更有用，因为没有前列腺癌患者PAP呈阳性而PA呈阴性。我们得出结论，在我们的大规模筛查系统中，PA应该是一种可靠的肿瘤标志物。
